J
J. Pape
Researcher at Charité
Publications - 9
Citations - 612
J. Pape is an academic researcher from Charité. The author has contributed to research in topics: Preeclampsia & Pregnancy. The author has an hindex of 4, co-authored 7 publications receiving 556 citations.
Papers
More filters
Journal ArticleDOI
An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia
Stefan Verlohren,Alberto Galindo,Dietmar Schlembach,Harald Zeisler,Ignacio Herraiz,Manfred G. Moertl,J. Pape,Joachim W. Dudenhausen,Barbara Denk,Holger Stepan +9 more
TL;DR: It is proposed that sFlt-1, PIGF, and sFelt-1/PIGF ratio may be of value in the prediction of PE and in the differential diagnosis of patients with atypical presentations of PE, and perhaps in the differentiation diagnosis of women with chronic hypertension suspected to develop superimposed PE.
Journal ArticleDOI
Prevalence of Agonistic Autoantibodies Against the Angiotensin II Type 1 Receptor and Soluble fms-Like Tyrosine Kinase 1 in a Gestational Age–Matched Case Study
Florian Herse,Stefan Verlohren,Katrin Wenzel,J. Pape,Dominik N. Müller,Susanne Modrow,Gerd Wallukat,Friedrich C. Luft,Christopher W.G. Redman,Ralf Dechend +9 more
TL;DR: It is concluded that AT1-AAs were common in patients with preeclampsia in a prospective case-control study, although sFlt-1 was a superior biomarker for early onset disease.
Journal ArticleDOI
The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction.
Katharina Schoofs,Ulrike Grittner,Theresa Engels,J. Pape,Barbara Denk,Wolfgang Henrich,Stefan Verlohren +6 more
TL;DR: The sFlt-1/PlGF ratio can identify pathologic pregnancy outcomes such as IUGR and PE before clinical diagnosis and is predictive for future pregnancy outcome and risk of developing preeclampsia.
Journal ArticleDOI
Automated measurement of sFlt1, PlGF and sFlt1/PlGF ratio in differential diagnosis of hypertensive pregnancy disorders
TL;DR: The automated measurement of sFlt1/PlGF is a reliable diagnostic tool in differential diagnosis of hypertensive pregnancy disorders and gives additional valuable information for clinical management.
Journal ArticleDOI
PP051. Prediction of preeclampsia with the sFlt-1/PLGF ratio: impact of the slope of repeated measurements
TL;DR: The sFlt-1/PlGF ratio is able to identify pathologic pregnancy outcomes in gestational weeks 24-36 and is predictive of further pregnancy outcome and the risk of developing preeclampsia.